Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Updated results from iMMagine–1
OR
[magic_login_form]
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Studies / Trials Discussed
ID 256 – Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1
Studies/trials discussed:
ID 256 – Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.